EP
EDIT icon

Essential Partners’s Editas Medicine EDIT Stock Holding History

Essential Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.26K Buy
1,624
+141
+10% +$412 ﹤0.01% 1520
2026
Q1 		$3.66K Buy
1,483
+770
+108% +$1.63K ﹤0.01% 1726
2025
Q4 		$1.46K Hold
713
– – ﹤0.01% 1906
2025
Q3 		$2.47K Hold
713
– – ﹤0.01% 1719
2025
Q2 		$1.57K Buy
+713
New +$1.17K ﹤0.01% 1388

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Essential Partners's EDIT Position: Q2 2026 in Review

Essential Partners increased its Editas Medicine (EDIT) stake by 9.5% in Q2 2026, buying an estimated $412 and bringing the position to 1,624 shares worth $5.26K. The position accounts for ﹤0.01% of the portfolio, ranked #1520.

Essential Partners first reported a position in EDIT in Q2 2025 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Essential Partners held 1,624 shares of Editas Medicine worth $5.26K as of Q2 2026.
  • Essential Partners bought 141 Editas Medicine shares in Q2 2026, an estimated $412.
  • Editas Medicine made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1520 holding.
  • Essential Partners first reported a position in Editas Medicine in Q2 2025 and has held it in 5 quarters since.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.